Tempol Archives - Adamis Pharmaceuticals

February 27, 2023: Adamis Pharmaceuticals announces merger with DMK Pharmaceuticals. Read the press release. Watch the video.

Fe-S cofactors in the SARS-CoV-2 RNA-dependent<br>RNA polymerase are potential antiviral targets

Emerging Infectious Diseases and<br>Diagnosis Journal

Sign Up For Adamis Email Alerts

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.

Category: Tempol

Fe-S cofactors in the SARS-CoV-2 RNA-dependent<br>RNA polymerase are potential antiviral targets

Emerging Infectious Diseases and<br>Diagnosis Journal

Sign Up For Adamis Email Alerts

COMPANY

PRODUCTS

PIPELINE

INVESTORS & MEDIA

CONNECT